Inhibrx Biosciences, Inc. (INBX)Healthcare | Biotechnology | La Jolla, United States | NasdaqGS
90.53 USD
-4.48
(-4.715%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
After hours: 90.53 |
Hot Take ↕ | Oct. 10, 2026, 3:03 a.m. EDT
The fundamental reality here is stark: Inhibrx is a cash-burning biotech with negative earnings, negative book value, and no dividend to speak of. The balance sheet is fragile, with debt exceeding cash reserves, forcing the company to rely entirely on capital markets for survival. While the recent price action shows a massive recovery from 2024 lows, this is driven by speculative hype around its pipeline assets, not sustainable profitability. The options market confirms this sentiment; traders are buying deep out-of-the-money calls hoping for a miracle event, while hedging against a failure of those events. The statistical forecast model offers no help, showing a weak, noisy signal that cannot be trusted. This is not a buy-and-hold opportunity; it is a high-risk venture play where the odds favor the downside unless a major clinical milestone occurs soon. The valuation metrics are meaningless due to lack of earnings, making the current price a pure reflection of sentiment on the drug candidates. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.210675 |
| AutoETS | 0.212780 |
| AutoTheta | 0.248720 |
| AutoARIMA | 0.367669 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 10.57 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.314 |
| Excess Kurtosis | -1.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,332,389,760 |
| Forward P/E | -10.33 |
| Beta | 3.82 |
| Website | https://inhibrx.com |
As of Oct. 10, 2026, 3:03 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. Call Open Interest is heavily concentrated at strikes significantly above the current price (120, 125, 160), suggesting a 'lottery ticket' mentality where traders bet on a massive surge to double the stock. Conversely, Put Open Interest forms a dense wall at lower strikes (60, 70, 75), indicating a hedge against a drop to the 28-year lows. The imbalance in volume versus open interest at deep out-of-the-money strikes suggests active speculation on binary outcomes (clinical trial results or partnership deals) rather than a steady trend.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6006894 |
| Address1 | 11,025 North Torrey Pines Road |
| Address2 | Suite 140 |
| All Time High | 155.29 |
| All Time Low | 10.8 |
| Ask | 119.92 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 215,940 |
| Average Daily Volume3 Month | 279,896 |
| Average Volume | 279,896 |
| Average Volume10Days | 215,940 |
| Beta | 3.822 |
| Bid | 67.68 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | -3.602 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 90.53 |
| Current Ratio | 5.067 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 96.1 |
| Day Low | 90.0 |
| Display Name | Inhibrx Biosciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -125,604,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.992 |
| Enterprise Value | 1,380,671,744 |
| Eps Current Year | -9.255 |
| Eps Forward | -8.76 |
| Eps Trailing Twelve Months | -8.88 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 103.377 |
| Fifty Day Average Change | -12.847 |
| Fifty Day Average Change Percent | -0.12427329 |
| Fifty Two Week Change Percent | 160.06894 |
| Fifty Two Week High | 155.29 |
| Fifty Two Week High Change | -64.759995 |
| Fifty Two Week High Change Percent | -0.4170262 |
| Fifty Two Week Low | 28.16 |
| Fifty Two Week Low Change | 62.37 |
| Fifty Two Week Low Change Percent | 2.2148438 |
| Fifty Two Week Range | 28.16 - 155.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,716,989,400,000 |
| Float Shares | 8,588,932 |
| Forward Eps | -8.76 |
| Forward P E | -10.334475 |
| Free Cashflow | -85,104,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 109 |
| Fullday Change | -4.4800034 |
| Fullday Change Percent | -4.7152967 |
| Fullday Price | 90.53 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -103,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23084 |
| Held Percent Institutions | 0.90650004 |
| Implied Shares Outstanding | 14,717,660 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. |
| Long Name | Inhibrx Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,332,389,760 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1873020488 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -138,180,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,477,505,887 |
| Number Of Analyst Opinions | 3 |
| Open | 94.03 |
| Operating Cashflow | -131,889,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 795 4220 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 90.53 |
| Post Market Time | 1,791,840,714 |
| Previous Close | 95.01 |
| Price Eps Current Year | -9.781739 |
| Price Hint | 2 |
| Price To Book | -25.133259 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 4.756 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -4.48 |
| Regular Market Change Percent | -4.7153 |
| Regular Market Day High | 96.1 |
| Regular Market Day Low | 90.0 |
| Regular Market Day Range | 90.0 - 96.1 |
| Regular Market Open | 94.03 |
| Regular Market Previous Close | 95.01 |
| Regular Market Price | 90.53 |
| Regular Market Time | 1,791,835,201 |
| Regular Market Volume | 214,035 |
| Return On Assets | -0.43611 |
| Return On Equity | -17.735981 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 14,717,660 |
| Shares Percent Shares Out | 0.2332 |
| Shares Short | 3,432,642 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,297,743 |
| Short Name | Inhibrx Biosciences, Inc. |
| Short Percent Of Float | 0.3114 |
| Short Ratio | 9.66 |
| Source Interval | 15 |
| State | CA |
| Symbol | INBX |
| Target High Price | 325.0 |
| Target Low Price | 230.0 |
| Target Mean Price | 266.66666 |
| Target Median Price | 245.0 |
| Total Cash | 133,344,000 |
| Total Cash Per Share | 9.06 |
| Total Debt | 181,626,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 91.36135 |
| Two Hundred Day Average Change | -0.83135223 |
| Two Hundred Day Average Change Percent | -0.0090996055 |
| Type Disp | Equity |
| Volume | 214,035 |
| Website | https://inhibrx.com |
| Zip | 92,037 |